DAC and CLAM are equally effective as early second induction in newly diagnosed AML patients with persistent leukemia in early bone marrow evaluation – a retrospective analysis of Polish Adult Leukemia Group
Kamil Brzozowski(Medical University of Lodz), Agnieszka Wierzbowska(Medical University of Lodz), Ewa Wawrzyniak(Medical University of Lodz), Janusz Hałka(Wojskowy Instytut Medycyny Lotniczej), Marek Hus(Medical University of Lublin), Marta Sobas, Agata Obara(Holy Cross University), Elżbieta Wiater(Copernicus Memorial Hospital), Łukasz Bołkuń(Medical University of Białystok), Edyta Cichocka(Nicolaus Copernicus University), Grzegorz Helbig(Medical University of Silesia), Elżbieta Patkowska(Institute for Transfusion Medicine), Krzysztof Gawroński(Medical University of Warsaw), Małgorzata Raźny, Tomasz Gromek(Medical University of Lublin), Martyna Włodarczyk(Medical University of Silesia), Andrzej B Szczepanik(Poznan University of Medical Sciences), Agnieszka Pluta
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162